About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5775603
Allelic
Composition
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-ERBB2)#Jjz/0
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• mice treated with doxycycline for 2 weeks exhibit increased lateral branching and ductal ectasia of adult mammary ductal trees
• doxycycline treatment beginning at 8 weeks of age results in the development of mammary tumors with 100% penetrance and median latency of about 2 months
• tumors are consistent with moderate to poorly differentiated adenocarcinoma admixed with foci of ductal carcinoma in situ resembling human HER2-positive breast cancers
• tumor cell apoptosis and reduced tumor cellularity are seen within 24-48 hours of doxycycline removal, followed by tumor regression within 4-5 days
• lapatinib treatment results in arrest of tumor growth and/or regression
• about 2/3 of mice develop a recurrent mammary gland tumor when doxycycline is withdrawn; recurrent tumors do not express ERBB2 and have different expression profiles than primary tumors
• trastuzumab treatment results in in tumor regression and subsequent regrowth in two tumors despite continued therapy, indicating development of trastuzumab-resistant tumors
• primary tumor cells treated with both lapatinib and trastuzumab exhibit some growth inhibition which is enhanced further with the addition of the CDK4/6 inhibitor abemaciclib

integument
• mice treated with doxycycline for 2 weeks exhibit increased lateral branching and ductal ectasia of adult mammary ductal trees
• doxycycline treatment beginning at 8 weeks of age results in the development of mammary tumors with 100% penetrance and median latency of about 2 months
• tumors are consistent with moderate to poorly differentiated adenocarcinoma admixed with foci of ductal carcinoma in situ resembling human HER2-positive breast cancers
• tumor cell apoptosis and reduced tumor cellularity are seen within 24-48 hours of doxycycline removal, followed by tumor regression within 4-5 days
• lapatinib treatment results in arrest of tumor growth and/or regression
• about 2/3 of mice develop a recurrent mammary gland tumor when doxycycline is withdrawn; recurrent tumors do not express ERBB2 and have different expression profiles than primary tumors
• trastuzumab treatment results in in tumor regression and subsequent regrowth in two tumors despite continued therapy, indicating development of trastuzumab-resistant tumors
• primary tumor cells treated with both lapatinib and trastuzumab exhibit some growth inhibition which is enhanced further with the addition of the CDK4/6 inhibitor abemaciclib

neoplasm
• doxycycline treatment beginning at 8 weeks of age results in the development of mammary tumors with 100% penetrance and median latency of about 2 months
• tumors are consistent with moderate to poorly differentiated adenocarcinoma admixed with foci of ductal carcinoma in situ resembling human HER2-positive breast cancers
• tumor cell apoptosis and reduced tumor cellularity are seen within 24-48 hours of doxycycline removal, followed by tumor regression within 4-5 days
• lapatinib treatment results in arrest of tumor growth and/or regression
• about 2/3 of mice develop a recurrent mammary gland tumor when doxycycline is withdrawn; recurrent tumors do not express ERBB2 and have different expression profiles than primary tumors
• trastuzumab treatment results in in tumor regression and subsequent regrowth in two tumors despite continued therapy, indicating development of trastuzumab-resistant tumors
• primary tumor cells treated with both lapatinib and trastuzumab exhibit some growth inhibition which is enhanced further with the addition of the CDK4/6 inhibitor abemaciclib
• 80% of mice show lung metastases after 16 weeks of sustained doxycycline induction
• lung metastases are seen in only 15% of mice induced for 16 weeks and subsequently maintained on a doxycycline-free diet for 4 weeks

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
breast cancer DOID:1612 OMIM:114480
J:231766


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/12/2024
MGI 6.23
The Jackson Laboratory